Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, is set to release its 2025 full-year financial results on March 30, 2026, after market close in the United States [1]. Group 1: Financial Results Announcement - The company will announce its 2025 full-year financial results on March 30, 2026 [1]. - A conference call will be held on March 31, 2026, at 8:00 am (New York) and 2:00 pm (Paris) to discuss the results [2]. - Participants must register in advance to join the conference call and ask questions [2]. Group 2: Company Overview - Inventiva focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [4]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for treating adult patients with MASH [4]. - Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market under the ticker IVA [5].

Core Viewpoint - Weatherford International plc will host a conference call on April 22, 2026, to discuss its first-quarter results for the period ending March 31, 2026 [1]. Group 1: Conference Call Details - The conference call will start at 8:30 a.m. Eastern Time (7:30 a.m. Central Time) [2]. - Participants can join the call via a live webcast or by dialing specific numbers for U.S. and international access [3]. - A telephonic replay of the conference call will be available until May 05, 2026, at 5:00 p.m. Eastern Time [4]. Group 2: Company Overview - Weatherford provides innovative energy services that combine proven technologies with advanced digitalization to enhance value and return on investment [5]. - The company operates in approximately 75 countries, employing around 16,700 team members from about 105 nationalities across approximately 305 locations [5].

Core Viewpoint - Timbercreek Financial has declared a monthly cash dividend of $0.0575 per common share, payable on April 15, 2026, to shareholders of record on March 31, 2026 [1] Group 1: Dividend Information - The company offers a Dividend Reinvestment Plan (the "Plan") that allows holders of common shares to reinvest cash dividends at a potential discount without incurring commissions or fees [2] - Under the Plan, common shares will be acquired either in the open market at prevailing prices or issued from treasury at 98% of the average market price for the five trading days ending on the third business day before the dividend payment date [3] Group 2: Enrollment and Participation - Common shares acquired under the Plan will be automatically enrolled, and shareholders holding shares through brokers or other nominees must enroll for reinvestment through their nominee [4] Group 3: Company Overview - Timbercreek Financial is a leading non-bank commercial real estate lender, providing structured financing solutions to commercial real estate investors with a focus on faster execution and flexible terms [5] - The company employs thorough underwriting, active management, and strong governance to target strong risk-adjusted returns for investors [5]

Core Insights - Battalion Oil Corporation reported its financial and operational results for Q4 2025, highlighting significant operational and strategic progress despite a decrease in production and revenue compared to Q4 2024 [1][5]. Financial Performance - Average daily net production for Q4 2025 was 11,207 Boe/d (48% oil), down from 12,750 Boe/d (55% oil) in Q4 2024. Total operating revenue decreased to $32.3 million from $49.7 million in the same period [5]. - The decline in revenue was primarily due to an $11.54 decrease per Boe in average realized prices and a decrease of approximately 1,543 Boe/d in average daily production [5]. - The company reported a net loss available to common stockholders of $12.5 million, equating to a net loss of $0.76 per share. Adjusted diluted net loss was $19.2 million or $1.16 per share [9]. Operational Highlights - The company successfully terminated a gas treating agreement and negotiated a new long-term agreement, which improved production reliability [3][4]. - Production from the core Monument Draw asset increased by approximately 30% since early December 2025 due to enhanced gas treating capacity [7]. - Battalion completed the sale of its West Quito assets for net proceeds of $60.1 million, representing about 10% of its proved reserves as of December 31, 2025 [7]. Cost Management - Lease operating and workover expenses rose to $12.86 per Boe in Q4 2025 from $11.26 per Boe in Q4 2024, attributed to increased repairs and maintenance costs [6]. - General and administrative expenses decreased to $4.42 per Boe in Q4 2025 from $6.04 per Boe in Q4 2024, mainly due to lower merger and refinancing costs [6][8]. Liquidity and Balance Sheet - As of December 31, 2025, the company had $208.1 million in term loan indebtedness and total liquidity of $28.0 million in cash and cash equivalents [10]. - The company prepaid $40.0 million in term loan debt in February 2026 following the West Quito divestiture [11]. Future Outlook - Battalion's strategic moves, including the acquisition of contiguous acreage and the establishment of a reliable gas treating arrangement, position the company for future growth [3][4].

Core Viewpoint - Rogers Communications Inc. is set to release its first quarter 2026 financial results on April 22, 2026, before the North American markets open, followed by a teleconference to discuss the results and outlook [1]. Financial Results Announcement - The financial results will be distributed via newswire and made available on the company's investor relations website [1]. - A teleconference will be held at 8:00 a.m. ET on the same day to discuss the results with the investment community [1]. Teleconference Access - A live webcast of the teleconference will be accessible on the investor relations section of Rogers' website [2]. - Participants can join the teleconference by calling 647-361-2258 or toll-free at 1-844-282-4459, using passcode 3793238 for access [2]. Presentation Archive - An archive of the presentation will be available on the investor relations website after the teleconference [3]. - A telephonic re-broadcast will be available for two weeks post-teleconference at 1-855-669-9658, with access code 5372834 [3]. Annual General Meeting - Rogers Communications Inc. will hold its Annual General Meeting of Shareholders on April 22, 2026, at 11:00 a.m. ET, in a hybrid format at 333 Bloor Street East, Toronto, Ontario, and online via webcast [4]. Company Overview - Rogers is a leading communications, sports, and entertainment company in Canada, publicly traded on the Toronto Stock Exchange and the New York Stock Exchange [5].

Core Insights - Exor reported a gross asset value of €37.1 billion at the end of 2025, with a net asset value (NAV) of €33.2 billion, reflecting a decrease in NAV per share by 8.1% compared to a 5.4% increase in the MSCI World Index [1][6]. Group 1: Portfolio Management - The company is simplifying its portfolio by divesting stakes in Iveco Group, GEDI, Lifenet, and NUO, which are expected to generate €2 billion in proceeds this year, achieving a total multiple of more than 1.4x on invested capital [2]. - Following these divestitures, Exor will have over €3.5 billion in cash available for new investments, positioning the company to pursue significant opportunities similar in scale to Philips [3]. Group 2: Financial Performance - Exor's performance was impacted by challenges at its largest companies, although this was partially offset by strong returns from Lingotto, which reached over $10 billion in assets under management [6]. - The company experienced inflows of €4.2 billion in 2025 and anticipates additional monetization proceeds, enhancing its ability to capitalize on investment opportunities [6]. - Exor's extended debt maturity provides financial flexibility, with a loan-to-value (LTV) ratio of 6.9%, significantly below the 15% target [6]. Group 3: Dividend Proposal - A proposed dividend of €0.49 per share is set for approval by the AGM, amounting to approximately €100 million, with payment scheduled for May 27 [6].

Core Insights - Tonix Pharmaceuticals announced the presentation of Phase 1 data on TNX-4800, a long-acting human monoclonal antibody for the seasonal prevention of Lyme disease, at the World Vaccine Congress Washington 2026 [1][3] Group 1: TNX-4800 Overview - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease, and has shown 95% effectiveness in preventing infection in animal studies [4][6] - The antibody is designed to provide immunity within two days of administration and maintain protective antibody levels throughout the tick season, offering a pre-exposure prophylaxis without relying on the recipient's immune system [4][6] - The company expects to have GMP investigational product available for clinical testing in early 2027, with a field study anticipated to begin enrollment in the first half of 2027 [5] Group 2: TNX-801 Overview - TNX-801 is a live attenuated horsepox virus vaccine candidate aimed at preventing smallpox and mpox, expected to enter Phase 1 studies in 2027 pending FDA clearance [8] Group 3: Phase 1 Study Details - The Phase 1 study of TNX-4800 involved 44 subjects, with 41 completing the study, assessing safety, tolerability, pharmacokinetics, and immunogenicity [6] - Drug exposure increased approximately 25 times for a 20 times increase in dose, with serum TNX-4800 measurable within 24 hours and remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [6] - The mean half-life of TNX-4800 ranged from 62-69 days, with most adverse events being mild or moderate, indicating that TNX-4800 is generally safe and well tolerated [6] Group 4: Lyme Disease Context - Lyme disease is the most common vector-borne infection in the U.S., caused by Borrelia burgdorferi, with increasing incidence due to climate changes affecting tick habitats [7] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated infections potentially spreading to joints, heart, and nervous system [7]

Tórshavn, Faroe Islands, 2026-03-23 (GLOBE NEWSWIRE) -- P/F Atlantic Petroleum (NASDAQ OMX: ATLA DKK) hereby announces an update to the financial calendar for 2026: Referring to press release released earlier today. The annual accounts for 2025 which in the financial calendar were scheduled to be issued on 31st March 2026 are now, pending a debt solution , now scheduled to be issued 30th April 2026 The Annual General Metting which in the financial calendar was scheduled to be held on 30th April 2026 is now ...

Core Viewpoint - Garden Stage Limited has regained compliance with Nasdaq's minimum bid price requirement, closing the matter with Nasdaq [1][3]. Group 1: Compliance Notification - On March 20, 2026, Garden Stage received a notification from Nasdaq confirming compliance with the minimum bid price requirement [1]. - The company was initially notified on September 5, 2025, regarding its failure to maintain a minimum closing bid price of $1.00 per share for 30 consecutive trading days [2]. - Following the initial notification, the company was granted a 180-day period to regain compliance, which was later extended by an additional 180 days [2]. Group 2: Share Consolidation - On March 6, 2026, the company executed a share consolidation at a ratio of 200 for 1 to help meet the bid price requirement [2]. Group 3: Operational Overview - Garden Stage Limited is a holding company based in the Cayman Islands, with operations conducted through two wholly-owned subsidiaries in Hong Kong: I Win Securities Limited and I Win Asset Management Limited [4]. - I Win Securities Limited is licensed for Type 1 regulated activities and is a participant of the Hong Kong Stock Exchange [4]. - I Win Asset Management Limited is licensed for Type 4 and Type 9 regulated activities under the Securities and Futures Ordinance in Hong Kong [4].

Core Insights - Context Therapeutics Inc. is advancing its pipeline of T cell-engaging bispecific antibodies for solid tumors, with significant progress reported in 2025 [2][4] - The company expects to provide Phase 1a interim data for CTIM-76 in June 2026 and for CT-95 in September 2026, with plans to dose the first patient in the CT-202 Phase 1 trial in Q3 2026 [2][4][6] - As of December 31, 2025, the company has cash and cash equivalents of $66.0 million, which is expected to fund operations into mid-2027 [3][10] Pipeline Highlights - CTIM-76 is in Phase 1 dose escalation for patients with ovarian, endometrial, or testicular cancer, with a completion of the weekly dose escalation phase anticipated in the first half of 2026 [4][6] - CT-95 is in Phase 1 dose escalation for patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancer, with interim data expected in September 2026 [6] - CT-202 is in preclinical development for patients with bladder, non-small cell lung, colorectal, breast, and head and neck cancer, with the first patient expected to be dosed in Q3 2026 [6] Financial Results - For the fiscal year 2025, research and development expenses were $31.9 million, up from $22.7 million in 2024, primarily due to increased costs associated with CT-202 and CTIM-76 [10][11] - General and administrative expenses rose to $7.8 million in 2025 from $7.2 million in 2024, driven by higher personnel-related costs [10][11] - The company reported a net loss of $36.1 million for 2025, compared to a net loss of $26.7 million in 2024, with a net loss per share of $0.38 [10][11]